CAJ | 학술논문

目的：通过研究不同药物配伍中木通的毒性成分马兜铃酸A的含量，考察药物配伍对木通毒性的影响，以指导临床有效地安全用药。方法：通过对龙胆泻肝汤中的药物比例进行调节，将其分为木通组、全处方组、木通＋清热组、木通＋滋阴组、木通＋利水组以及阴性对照组（即全处方除去木通）6组。采用反相高效液相色谱法对各个组别中马兜铃酸A的含量进行测定，比较不同组别间马兜铃酸A的含量差别。结果：通过实验可知，以木通组作为参考组别，全处方组中马兜铃酸A含量最低，木通毒性最小；木通＋滋阴组中木通毒性也明显降低；其他组别中马兜铃酸 A 含量同样较木通组较低，但降低幅度较小。结论：通过实验数据可知，当处方中药物配伍发生变化时，木通的毒性成分含量也随之改变。准确有效的处方配伍可以将木通毒性明显降低，提高药物疗效，减少毒副作用的发生，保证用药的安全性。因此，中药的配伍研究在合理安全用药上具有举足轻重的作用。
목적：통과연구불동약물배오중목통적독성성분마두령산A적함량，고찰약물배오대목통독성적영향，이지도림상유효지안전용약。방법：통과대룡담사간탕중적약물비례진행조절，장기분위목통조、전처방조、목통＋청열조、목통＋자음조、목통＋이수조이급음성대조조（즉전처방제거목통）6조。채용반상고효액상색보법대각개조별중마두령산A적함량진행측정，비교불동조별간마두령산A적함량차별。결과：통과실험가지，이목통조작위삼고조별，전처방조중마두령산A함량최저，목통독성최소；목통＋자음조중목통독성야명현강저；기타조별중마두령산 A 함량동양교목통조교저，단강저폭도교소。결론：통과실험수거가지，당처방중약물배오발생변화시，목통적독성성분함량야수지개변。준학유효적처방배오가이장목통독성명현강저，제고약물료효，감소독부작용적발생，보증용약적안전성。인차，중약적배오연구재합리안전용약상구유거족경중적작용。
Objective:According to study the content of Mutong toxic components aristolochic acid A in different combinations, to observe effects of drug compatibility on toxicity of Mutong, in order to guide safe medication in clinic. Methods:By adjusting the ratio of the Longdan Xiegan decoction, six groups were divided based on proportion of drug, content of aristolochic acid A in six groups were measured by reversed-phase high-performance liquid chromatography. Results: Mutong group as the reference group, content of aristolochic acid A in the full prescribing group was lowest, and the Mutong with minimal toxicity; toxicity of Mutong in Mutong plus Lishui group was obviously lower; in another three groups, it was lower than Mutong group. Conclusion: Toxicity of Mutong changed following the changes of drug compatibility. Reasonable prescription compatibility can reduce toxicity, improve drug efficacy, reduce side effects, ensure the safety of medication. Therefore, the compatibility of TCM medicine play a pivotal role in safe medication.